BiotechTube
aTen Therapeutics

aTen Therapeutics

London, United Kingdom· Est.
atentherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18.5M

Overview

aTen Therapeutics is a UK-based, private biotech developing antibody therapies targeting a key biological pathway in cancer. The company is in the preclinical stage with its lead asset, Tensinumab (ATN-E11), which has demonstrated tumor growth inhibition in experimental models. In August 2022, it secured a £282k Innovate UK grant to advance its breast cancer program. Led by CEO Ian Abercrombie, the company is pre-revenue and building its foundational technology platform.

Oncology

Technology Platform

Platform for developing novel therapeutic human antibodies targeting a fundamental control pathway associated with cancer and other major diseases.

Funding History

2
Total raised:$18.5M
Series A$15M
Seed$3.5M

Opportunities

The primary opportunity lies in the large and growing oncology market, particularly breast cancer, where novel targeted therapies are in high demand.
Success with its lead candidate could validate its platform, enabling expansion into other cancer types and potentially other disease areas linked to the same fundamental pathway.

Risk Factors

Key risks include the high failure rate of preclinical assets in translation to human efficacy and safety, a reliance on securing significant additional funding beyond its initial grant, and intense competition in the oncology antibody therapeutics space.

Competitive Landscape

aTen operates in the highly competitive field of oncology antibody development, competing with large pharmaceutical companies and numerous biotechs. Its differentiation hinges on the novelty and fundamental importance of its undisclosed target pathway. Success depends on demonstrating superior or unique efficacy/safety profiles compared to existing targeted therapies and immunotherapies.

More companies in Oncology (General) →More companies in United Kingdom →